Register entry
LNHC Inc.
- Registered sites
- 1
- Drug products
- 1
- Live patents
- 16
- Countries
- 1
- Base
- United States
Authorisation
Registered operations
What the FDA has registered these sites to do. This is the regulatory record, not a marketing claim.
Active ingredient (API) manufactureLabelling
Sites
Facilities
1| Site | Location | Operations | FEI |
|---|---|---|---|
| LNHC Inc. | Durham, NCUnited States | Active ingredient (API) manufacture, Labelling | 3035364814 |
Exclusivity
Patents
16Unexpired Orange Book patents where this company is the application holder.
| Product | Active ingredient | Expiry |
|---|---|---|
| XEGLYZE | ABAMETAPIR | Oct 2026 |
| XEGLYZE | ABAMETAPIR | Dec 2034 |
| XEPI | OZENOXACIN | Dec 2029 |
| XEPI | OZENOXACIN | Jan 2032 |
| ZELSUVMI | BERDAZIMER SODIUM | Aug 2030 |
| ZELSUVMI | BERDAZIMER SODIUM | Sept 2031 |
| ZELSUVMI | BERDAZIMER SODIUM | Jul 2032 |
| ZELSUVMI | BERDAZIMER SODIUM | Feb 2034 |
| ZELSUVMI | BERDAZIMER SODIUM | Feb 2034 |
| ZELSUVMI | BERDAZIMER SODIUM | Nov 2034 |
| ZELSUVMI | BERDAZIMER SODIUM | Jul 2035 |
Catalogue
Marketed products
1Showing 1 of 1.
| Brand | Generic name | Form | Category |
|---|---|---|---|
| ZELSUVMI | berdazimer | KIT | NDA |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.